Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Stock Information for Lipocine Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Lipocine Inc.

2026 Asset Growth: Why Federal Compliance Is the New Metric
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)
Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.